PapersPMID:22161420
Withdrawn by Cochrane in May 2012; superseded by the update (PMID 22592726). Retraction Watch gives the reason: concerns about results/conclusions; error in methods.
Coenzyme Q10 for Parkinson's disease.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“In safety outcomes, only the risk ratios (RR) of pharyngitis (RR 1.04, 95% CI 0.18 to 5.89) and diarrhea (RR 1.39, 95% CI 0.62 to 3.16) are mild elevated between coenzyme Q10 therapy and placebo and there were no differences in the number of withdrawals due to adverse effects (RR 0.61, 95% CI 0.23 to 1.62).”
- Study
- meta-analysis
- Effect
- 0.61 risk ratio, 95% CI 0.23 to 1.62
- Dose studied
- 1200 mg/d for 16 months
- Population
- patients with early and midstage Parkinson's disease; Cochrane meta-analysis of 4 RCTs, 452 patients, coenzyme Q10 versus placebo
Study record
- Design
- meta-analysis
- Species
- human
- Population
- patients with early and midstage Parkinson's disease
- Participants
- 452
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 5